Yin Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Interests
Yin Zhou has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Fiona Mary Walter
Centre for Cancer Screening, Prevention and Early Diagnosis, Wolfson Institute of Population Health, Queen Mary University of London, London, United Kingdom
7 shared publications - Georgios Lyratzopoulos
Epidemiology of Cancer Healthcare and Outcomes Group, University College London, London, UK
7 shared publications - Gary A. Abel
Department of Health and Community Sciences, University of Exeter, Exeter, UK
6 shared publications Fiona M Walter
Centre for Cancer Screening, Prevention, and Early Diagnosis, Wolfson Institute of Population Health, Queen Mary University of London, London, UK
5 shared publicationsGeorgios Lyratzopoulos
Institute of Epidemiology and Health Care University College London London UK
5 shared publications- William Hamilton
University of Exeter, Exeter, United Kingdom
4 shared publications
Latest Publications
- 12 May 2026
- Published by Elsevier in Public Health
- Vol. 256, 106312
Concordance with primary care referral guidelines for breast lumps in Singapore: A retrospective cohort study
- 12 May 2026
- Published by Elsevier in Public Health
- Vol. 256, 106312
Concordance with primary care referral guidelines for breast lumps in Singapore: A retrospective cohort study
- Open Access
- 7 March 2026
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 65, 101638
Cancer risk in patients with recurrent or persistent symptoms: a systematic review
- 7 March 2026
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 65, 101638
Open AccessCancer risk in patients with recurrent or persistent symptoms: a systematic review
- Open Access
- 2 March 2026
- Published by Elsevier in The Lancet Primary Care
- Vol. 2 (2)
Defining recurrent urinary tract infections and quantifying bladder cancer risk in primary care in England: a nationwide case–control study
- 2 March 2026
- Published by Elsevier in The Lancet Primary Care
- Vol. 2 (2)
Open AccessDefining recurrent urinary tract infections and quantifying bladder cancer risk in primary care in England: a nationwide case–control study
- Open Access
- 4 February 2025
- Published by Wiley in BJUI Compass
- Vol. 6 (2) , e495
Sociodemographic landscape of suspected prostate cancer referrals and diagnoses across North East London
Objectives: The objective of this study is to identify healthcare inequities in referrals and diagnoses of suspected prostate cancer (PCa) in an ethnically diverse and socially deprived large urban region.Methods: Retrospective cohort study of 2‐Week Wait (2WW) suspected PCa patients (n = 12 947) referred to two acute NHS Trusts in North East London (NEL) from February 2019 to August 2023. Sociodemographics, diagnosis and pretreatment staging data were collected from patient records. We examined referral and diagnosis statistics, age at referral, radiological T‐stage at diagnosis, levels of deprivation by ethnicity and the impact of COVID‐19 pandemic lockdowns on proportion of referrals and diagnoses by ethnicity and T‐stage at diagnosis. Uni‐ and multivariable logistic regression was performed to identify predictors of locally advanced (T‐stage ≥T3) disease.Results: Of all referrals, 22% were diagnosed with PCa. There were no statistically significant differences in referrals, diagnoses or T‐stage of PCa by ethnicity during COVID lockdown versus non‐lockdown periods (p > 0.05). Compared to men from any other ethnicity, Black men (from Black British, Black African and Black Caribbean ethnic groups) were diagnosed at a younger age (mean = 65 years), had the highest age‐adjusted PCa incidence rate of 149 per 100 000 person‐years, were from the most deprived backgrounds, and were diagnosed with the highest proportion of localised PCa (74%). Multivariable analysis of a patient subgroup revealed age bands 71–80 years (OR 2.01, 95% CI 1.31–3.07) and >80 (OR 4.27, 95% CI 2.25–8.08) as independent positive predictors of locally advanced PCa, and Black ethnicity as an independent predictor of localised disease (OR 0.66, 95% CI 0.43–1.00). Limitations of this study include the exclusion of PCa cases diagnosed outside the 2WW pathway, as well as missing data on Prostate‐Specific Antigen (PSA) levels, distant radiological staging and histopathological findings.Conclusion: We identify disparities in PCa incidence, stage and age at presentation, as well as socio‐economic deprivation among Black men in NEL. Targeted efforts are needed to mitigate these healthcare inequities.
- 4 February 2025
- Published by Wiley in BJUI Compass
- Vol. 6 (2) , e495
Open AccessSociodemographic landscape of suspected prostate cancer referrals and diagnoses across North East London
Objectives: The objective of this study is to identify healthcare inequities in referrals and diagnoses of suspected prostate cancer (PCa) in an ethnically diverse and socially deprived large urban region.Methods: Retrospective cohort study of 2‐Week Wait (2WW) suspected PCa patients (n = 12 947) referred to two acute NHS Trusts in North East London (NEL) from February 2019 to August 2023. Sociodemographics, diagnosis and pretreatment staging data were collected from patient records. We examined referral and diagnosis statistics, age at referral, radiological T‐stage at diagnosis, levels of deprivation by ethnicity and the impact of COVID‐19 pandemic lockdowns on proportion of referrals and diagnoses by ethnicity and T‐stage at diagnosis. Uni‐ and multivariable logistic regression was performed to identify predictors of locally advanced (T‐stage ≥T3) disease.Results: Of all referrals, 22% were diagnosed with PCa. There were no statistically significant differences in referrals, diagnoses or T‐stage of PCa by ethnicity during COVID lockdown versus non‐lockdown periods (p > 0.05). Compared to men from any other ethnicity, Black men (from Black British, Black African and Black Caribbean ethnic groups) were diagnosed at a younger age (mean = 65 years), had the highest age‐adjusted PCa incidence rate of 149 per 100 000 person‐years, were from the most deprived backgrounds, and were diagnosed with the highest proportion of localised PCa (74%). Multivariable analysis of a patient subgroup revealed age bands 71–80 years (OR 2.01, 95% CI 1.31–3.07) and >80 (OR 4.27, 95% CI 2.25–8.08) as independent positive predictors of locally advanced PCa, and Black ethnicity as an independent predictor of localised disease (OR 0.66, 95% CI 0.43–1.00). Limitations of this study include the exclusion of PCa cases diagnosed outside the 2WW pathway, as well as missing data on Prostate‐Specific Antigen (PSA) levels, distant radiological staging and histopathological findings.Conclusion: We identify disparities in PCa incidence, stage and age at presentation, as well as socio‐economic deprivation among Black men in NEL. Targeted efforts are needed to mitigate these healthcare inequities.
- Open Access
- 26 April 2024
- Published by Elsevier in The Lancet Regional Health - Western Pacific
- Vol. 46, 101073
Addressing cancer care gaps through improved early cancer diagnosis in Singapore: research priorities to inform clinical practice
- 26 April 2024
- Published by Elsevier in The Lancet Regional Health - Western Pacific
- Vol. 46, 101073
Open AccessAddressing cancer care gaps through improved early cancer diagnosis in Singapore: research priorities to inform clinical practice
- Open Access
- 19 April 2024
- Published by Wiley in BJUI Compass
- Vol. 5 (7) , 805-812
Understanding symptom contribution to sex inequality in bladder and renal cancer stage at diagnosis
Background: Understanding sex‐specific factors contributing to advanced‐stage diagnosis can guide interventions to reduce sex inequality in patients with urological cancers.Method: We used linked primary care and cancer registry data to examine associations between symptoms and advanced‐stage in 1151 bladder cancer and 440 renal cancer patients diagnosed between January 2012 and December 2015 in England. We performed logistic regression, adjusting for sex, age, deprivation and routes to diagnosis, including interaction terms between symptoms and sex and symptoms and age.Results: Female sex (OR vs. men 1.89 [1.28–2.79]; p = 0.001) and patients presenting with urinary tract infections (OR 2.22 [1.34–3.69]) and abdominal symptoms (OR 2.19 [1.30–3.70]) were associated with increased odds of advanced‐stage bladder cancer (vs. haematuria, p = 0.016 for both). Women with haematuria and men with abdominal symptoms (compared with the opposite sex with the same presenting symptom) were more likely to have advanced‐stage bladder cancer. Neither sex nor symptom associations were observed for renal cancer.Conclusion: Non‐haematuria symptoms are associated with higher risk of advanced‐stage bladder cancer. Greater risk of advanced‐stage bladder cancer in women may reflect biological differences in haematuria onset and sex differences during diagnostic process. Identifying higher risk women with haematuria may reduce sex inequalities in bladder cancer outcomes.
- 19 April 2024
- Published by Wiley in BJUI Compass
- Vol. 5 (7) , 805-812
Open AccessUnderstanding symptom contribution to sex inequality in bladder and renal cancer stage at diagnosis
Background: Understanding sex‐specific factors contributing to advanced‐stage diagnosis can guide interventions to reduce sex inequality in patients with urological cancers.Method: We used linked primary care and cancer registry data to examine associations between symptoms and advanced‐stage in 1151 bladder cancer and 440 renal cancer patients diagnosed between January 2012 and December 2015 in England. We performed logistic regression, adjusting for sex, age, deprivation and routes to diagnosis, including interaction terms between symptoms and sex and symptoms and age.Results: Female sex (OR vs. men 1.89 [1.28–2.79]; p = 0.001) and patients presenting with urinary tract infections (OR 2.22 [1.34–3.69]) and abdominal symptoms (OR 2.19 [1.30–3.70]) were associated with increased odds of advanced‐stage bladder cancer (vs. haematuria, p = 0.016 for both). Women with haematuria and men with abdominal symptoms (compared with the opposite sex with the same presenting symptom) were more likely to have advanced‐stage bladder cancer. Neither sex nor symptom associations were observed for renal cancer.Conclusion: Non‐haematuria symptoms are associated with higher risk of advanced‐stage bladder cancer. Greater risk of advanced‐stage bladder cancer in women may reflect biological differences in haematuria onset and sex differences during diagnostic process. Identifying higher risk women with haematuria may reduce sex inequalities in bladder cancer outcomes.
- Open Access
- 30 November 2023
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 73 (737) , 534-535
Improving early diagnosis of pancreatic cancer in symptomatic patients
Early diagnosis is challenging since pancreatic cancer typically presents with non- specific symptoms that have low positive predictive values (PPVs) for cancer, such as abdominal pain, back pain, and weight loss.4 Consequently, time to referral can be long, as indicated by the relatively high proportion of patients with pancreatic cancer having multiple GP consultations before diagnosis.5 Jaundice is the sole alarm symptom,4 though its reported frequencies range from 12% to 43%, and tends to be a late sign of disease.6 Given the non-specific nature of many presentations, multidisciplinary centres (sometimes known as ‘vague’ or ‘non- specific’ symptom pathways) may improve timely diagnosis of pancreatic cancer. Indeed, an analysis from five such centres showed that, of 241 cancers diagnosed, 25 (10%) were pancreatic cancers.7
- 30 November 2023
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 73 (737) , 534-535
Open AccessImproving early diagnosis of pancreatic cancer in symptomatic patients
Early diagnosis is challenging since pancreatic cancer typically presents with non- specific symptoms that have low positive predictive values (PPVs) for cancer, such as abdominal pain, back pain, and weight loss.4 Consequently, time to referral can be long, as indicated by the relatively high proportion of patients with pancreatic cancer having multiple GP consultations before diagnosis.5 Jaundice is the sole alarm symptom,4 though its reported frequencies range from 12% to 43%, and tends to be a late sign of disease.6 Given the non-specific nature of many presentations, multidisciplinary centres (sometimes known as ‘vague’ or ‘non- specific’ symptom pathways) may improve timely diagnosis of pancreatic cancer. Indeed, an analysis from five such centres showed that, of 241 cancers diagnosed, 25 (10%) were pancreatic cancers.7
- 1 November 2023
- Published by Elsevier in The Lancet Oncology
- Vol. 24 (11) , 1166-1167
Understanding cancer risk in patients at lower risk to improve early cancer diagnosis
- 1 November 2023
- Published by Elsevier in The Lancet Oncology
- Vol. 24 (11) , 1166-1167
Understanding cancer risk in patients at lower risk to improve early cancer diagnosis
- Open Access
- 1 September 2023
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 74 (740) , e149-e155
Pre-diagnostic prescription patterns in bladder and renal cancer: a longitudinal linked data study
Background: Understanding pre-diagnostic prescribing activity could reveal windows during which more timely cancer investigation and detection may occur. Aim: To examine prescription patterns for common urological clinical features prior to renal and bladder cancer diagnoses. Design and setting: A retrospective cohort study was performed using electronic primary care and cancer registry data on patients with bladder and renal cancer, who received their diagnosis between April 2012 and December 2015 in England. Method: Primary care prescriptions up to 2 years pre- diagnosis were analysed for five groups of clinical features (irritative urological symptoms, obstructive symptoms, urinary tract infections [UTIs], genital infections, and atrophic vaginitis). Poisson regressions estimating the inflection point from which the rate of prescriptions increased from baseline were used to identify the start of diagnostic windows during which cancer could be detected. Results: A total of 48 094 prescriptions for 5322 patients were analysed. Inflection points for an increase in UTI prescriptions were identified 9 months pre- diagnosis for renal (95% confidence interval [CI] = 5.3 to 12.7) and bladder (95% CI = 7.4 to 10.6) cancers. For bladder cancer, the change in UTI antibiotic prescription rates occurred 4 months earlier in females (11 months pre- diagnosis, 95% CI = 9.7 to 12.3) than in males (7 months pre-diagnosis, 95% CI = 5.4 to 8.6). For other clinical features, no inflection points were identified and, as such, no diagnostic windows could be defined. Conclusion: Prescription rates for UTIs increased 9 months before bladder and renal cancer diagnoses, indicating that there is potential to expedite diagnosis of these cancers in patients presenting with features of UTI. The greatest opportunity for more timely diagnosis may be in females with bladder cancer, who experienced the earliest increase in UTI prescription rate.
- 1 September 2023
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 74 (740) , e149-e155
Open AccessPre-diagnostic prescription patterns in bladder and renal cancer: a longitudinal linked data study
Background: Understanding pre-diagnostic prescribing activity could reveal windows during which more timely cancer investigation and detection may occur. Aim: To examine prescription patterns for common urological clinical features prior to renal and bladder cancer diagnoses. Design and setting: A retrospective cohort study was performed using electronic primary care and cancer registry data on patients with bladder and renal cancer, who received their diagnosis between April 2012 and December 2015 in England. Method: Primary care prescriptions up to 2 years pre- diagnosis were analysed for five groups of clinical features (irritative urological symptoms, obstructive symptoms, urinary tract infections [UTIs], genital infections, and atrophic vaginitis). Poisson regressions estimating the inflection point from which the rate of prescriptions increased from baseline were used to identify the start of diagnostic windows during which cancer could be detected. Results: A total of 48 094 prescriptions for 5322 patients were analysed. Inflection points for an increase in UTI prescriptions were identified 9 months pre- diagnosis for renal (95% confidence interval [CI] = 5.3 to 12.7) and bladder (95% CI = 7.4 to 10.6) cancers. For bladder cancer, the change in UTI antibiotic prescription rates occurred 4 months earlier in females (11 months pre- diagnosis, 95% CI = 9.7 to 12.3) than in males (7 months pre-diagnosis, 95% CI = 5.4 to 8.6). For other clinical features, no inflection points were identified and, as such, no diagnostic windows could be defined. Conclusion: Prescription rates for UTIs increased 9 months before bladder and renal cancer diagnoses, indicating that there is potential to expedite diagnosis of these cancers in patients presenting with features of UTI. The greatest opportunity for more timely diagnosis may be in females with bladder cancer, who experienced the earliest increase in UTI prescription rate.
- Open Access
- 30 March 2023
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 73 (733) , e575-e585
Improving the diagnostic process for patients with possible bladder and kidney cancer: a mixed-methods study to identify potential missed diagnostic opportunities
Background: Patients with bladder and kidney cancer may experience diagnostic delays.Aim: To identify patterns of suboptimal care and contributors of potential missed diagnostic opportunities (MDOs).Design and setting: Prospective, mixed-methods study recruiting participants from nine general practices in Eastern England between June 2018 and October 2019.Method: Patients with possible bladder and kidney cancer were identified using eligibility criteria based on National Institute for Health and Care Excellence (NICE) guidelines for suspected cancer. Primary care records were reviewed at recruitment and at 1 year for data on symptoms, tests, referrals, and diagnosis. Referral predictors were examined using logistic regression. Semi-structured interviews were undertaken with 15 patients to explore their experiences of the diagnostic process, and these were analysed thematically.Results: Participants (n= 940) were mostly female (n= 657, 69.9%), with a median age of 71 years (interquartile range 64–77 years). In total, 268 (28.5%) received a referral and 465 (48.5%) had a final diagnosis of urinary tract infection (UTI). There were 33 (3.5%) patients who were diagnosed with cancer, including prostate (n= 17), bladder (n= 7), and upper urothelial tract (n= 1) cancers. Among referred patients, those who had a final diagnosis of UTI had the longest time to referral (median 81.5 days). Only one-third of patients with recurrent UTIs were referred despite meeting NICE referral guidelines. Qualitative findings revealed barriers during the diagnostic process, including inadequate clinical examination, female patients given repeated antibiotics without clinical reviews, and suboptimal communication of test results to patients.Conclusion: Older females with UTIs might be at increased risk of MDOs for cancer. Targeting barriers during the initial diagnostic assessment and follow-up might improve quality of diagnosis.
- 30 March 2023
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 73 (733) , e575-e585
Open AccessImproving the diagnostic process for patients with possible bladder and kidney cancer: a mixed-methods study to identify potential missed diagnostic opportunities
Background: Patients with bladder and kidney cancer may experience diagnostic delays.Aim: To identify patterns of suboptimal care and contributors of potential missed diagnostic opportunities (MDOs).Design and setting: Prospective, mixed-methods study recruiting participants from nine general practices in Eastern England between June 2018 and October 2019.Method: Patients with possible bladder and kidney cancer were identified using eligibility criteria based on National Institute for Health and Care Excellence (NICE) guidelines for suspected cancer. Primary care records were reviewed at recruitment and at 1 year for data on symptoms, tests, referrals, and diagnosis. Referral predictors were examined using logistic regression. Semi-structured interviews were undertaken with 15 patients to explore their experiences of the diagnostic process, and these were analysed thematically.Results: Participants (n= 940) were mostly female (n= 657, 69.9%), with a median age of 71 years (interquartile range 64–77 years). In total, 268 (28.5%) received a referral and 465 (48.5%) had a final diagnosis of urinary tract infection (UTI). There were 33 (3.5%) patients who were diagnosed with cancer, including prostate (n= 17), bladder (n= 7), and upper urothelial tract (n= 1) cancers. Among referred patients, those who had a final diagnosis of UTI had the longest time to referral (median 81.5 days). Only one-third of patients with recurrent UTIs were referred despite meeting NICE referral guidelines. Qualitative findings revealed barriers during the diagnostic process, including inadequate clinical examination, female patients given repeated antibiotics without clinical reviews, and suboptimal communication of test results to patients.Conclusion: Older females with UTIs might be at increased risk of MDOs for cancer. Targeting barriers during the initial diagnostic assessment and follow-up might improve quality of diagnosis.